About Charles River Laboratories
Charles River Laboratories, headquartered in Wilmington, Massachusetts, is a leading contract research organisation supporting drug discovery, safety assessment and manufacturing services.
Milestones
Milestones as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Joseph LaPlume
Mark Mintz
Shannon Parisotto
Products & Services
Products and services as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Research Models
Purpose-bred research rodents (over 140 stocks and strains) plus related services, supplied to drug developers since 1947.
Source: sec.govDiscovery and Safety Assessment services
Outsourced discovery research, bioanalysis and regulatory-required safety testing of drugs, vaccines, chemicals and medical devices.
Source: sec.govEndosafe
Endotoxin testing products and services used for required quality-control testing of injectable drugs and medical devices.
Source: sec.govCelsis
ATP-bioluminescence reagents and instruments for rapid detection of microbial contamination in pharma and consumer product manufacturing.
Source: sec.govAccugenix
ISO 17025-accredited contract lab network identifying and strain-typing bacteria and fungi from manufacturing facilities.
Source: sec.govBiologics Testing Services
Analytical, virology, bioassay and viral clearance testing supporting the safe manufacture of biologic drugs.
Source: sec.govFinancials & Irish Entities
From the annual reports Charles River Laboratories International, Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $4.02bn | — | — | −$144m | 10-K 2026 |
| Dec 2024 | $4.05bn | — | — | $22.2m | 10-K 2026 |
| Dec 2023 | $4.13bn | — | — | $475m | 10-K 2026 |
| Dec 2022 | $3.98bn | — | — | $486m | 10-K 2025 |
| Dec 2021 | $3.54bn | — | — | $391m | 10-K 2024 |
The company does not report a separate R&D expense line. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 3 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Charles River Laboratories Ireland Limited LTD - Private Company Limited by Shares | 211641 | 1994 | Dec 2025 |
| Charles River Development Ireland Limited LTD - Private Company Limited by Shares | 533444 | 2013 | Dec 2024 |
| Charles River Microbial Solutions International Limited LTD - Private Company Limited by Shares | 597383 | 2017 | Dec 2025 |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Charles River Laboratories International, Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.